The KU Leuven spinout has completed another tranche of funding for its series B round featuring investments from the university.
Remynd, a Belgium-based Alzheimer’s disease and diabetes treatment spinout of KU Leuven, has increased its series B funding to €24m ($29.1m) after securing investments from a consortium including the university.
The $14.6m second close of the series B round featured government-owned investment fund PMV, federal holding company SFPI-FPIM, BNP Paribas Fortis Private Equity and Korys Investments.
The company pulled in $13.6m for the initial close of the round in December 2018, which was co-led by PMV and Korys…
